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Abstract
Recent years witness rapid expansion of  applications of
proteomics to clinical research including non-malignant
lung disorders. These developments bring along the need
for standardisation of  proteomic experiments. This pa-
per briefly reviews basic methodical aspects of  applied
Introduction
Proteomics, a science dealing with proteome
– protein complement of  the genome, has
indeed reached pulmonary medicine. Though
still not vast, the number of  papers dealing
with description and/or identification of
novel proteins in lung pathobiology has been
increasing (e.g. 1-6) and currently, there has
been ongoing effort to link information from
gene expression and proteomics studies in
order to propose candidate molecules for
diagnostic and therapeutic purposes.
However, when engaged in proteomics, one
has to be aware of  possible pitfalls due to
sophisticated methodology and a number of
different formats of  obtained data. Of  course,
there are general methodical rules applicable
throughout laboratory medicine known as
Good Laboratory Practice7. Next, specific is-
sues appear that are pertinent only to pro-
teomics, adherence to which is mandatory for
obtaining meaningful data. These will be in
brief  described further and selected examples
shown based on usage of  SELDI-TOF MS
proteomic studies using SELDI-TOF mass spectrome-
try platform as example but also emphasizes general as-
pects of  quality assurance in proteomics.
Key-words: lung proteome, quality assurance, SELDI-
-TOF MS.
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platform (Surface Enhanced Laser Desorp-
tion Ionisation – Time of Flight Mass Spec-
trometry, ref. 1). The final level of  complexi-
ty is influenced by the purpose of  a proteomic
experiment: there will be different require-
ments for proteomic measurements directed
at discovery and validation of  new biomark-
ers than for experiments aimed at description
of  proteins involved in pathological disease
mechanisms. Discussing this topic is out of
scope of  our review, however one should be
aware of  existence of  working groups (e.g.
Proteomics Standards Initiative), which for-
mulate set of  guidelines for acquisition and
namely for adequate interpretation of  pro-
teomic data (e.g. 8). Important issue for pro-
teomic community is feasibility of  re-analyses
and verification of  results from different lab-
oratories. It is necessary to be able to com-
pare proteome coverage between different lab-
oratories or between different technical
platforms and for this purpose databases have
been already set8-10.
Any proteomic experiment, does not matter
if directed at screen for a candidate in dis-
ease pathology, for biomarker discovery or
for clinical prognostics, consists of  three
sequential stages (Scheme 1), methodical as-
pects of  which will now be discussed.
Preanalytical stage
Whatever is the nature of  the investigated
material (serum, bronchoalveolar lavage, spu-
tum), specimen collection must be standard-
ised and uniform procedures must also be
applied during manipulation with the biofluid
and its transport to the laboratory11,12: the
material should be kept cool (e.g. on ice, or
refrigerated to +4oC) and transported to the
laboratory as soon as possible. In the labo-
ratory, material should be divided into por-
tions (aliquots) and stored preferably in
-80oC; shock freezing down in liquid nitro-
gen is recommended.
Analytical stage
Instrument set-up
Regarding the instrumentation, standard
conditions are necessary: for example for
SELDI-TOF MS, vacuum and other param-
eters such as number of  laser shots should
be set as required by the manual, for two di-
mensional gel electrophoresis appropriate
temperature and constant power supply are
necessary. Regular calibration (at least week-
ly) of  an instrument is crucial12,13 and ob-
tained data (for SELDI-TOF MS) should lie
within the estimated range of  mass/charge
ratio, peak intensity and resolution and sig-
nal to noise ratio (for brief description see
section “Postanalytical stage”).
Samples
Work with samples should be organized so that
minimal variations are introduced when load-
ing the samples, e.g. in case of  SELDI-TOF
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Scheme 1. Sequence of stages of a proteomic experi-
ment using example of SELDI-TOF mass spectrometry
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MS manual pipetting has been superseded by
robotic spotting. Samples should be run in at
least duplicates, preferably in triplicates. Impor-
tantly, repeated freeze/thaw cycles must be
avoided when processing the samples.
Postanalytical stage
After the measurements, data processing is
the most important part of  proteomic ex-
periments. In most cases, analysis of  the raw
data from an instrument is performed by
software, which requires setting of  critical
parameters by an operator. For SELDI-TOF
MS these are: mass window, signal to noise
ratio and value of  normalisation factor. Be-
cause the above parameters are specific for
SELDI-TOF MS, only a brief  description
follows. Basically, mass accuracy reflects spe-
cific aim of the experiment and is different
for profiling and identification purposes. By
manipulating with signal to noise (back-
ground) ratio, one can achieve more precise
measurement and lower detection limits. For
clinical samples, during the normalisation
step, software corrects the data such that all
samples have the same mean of  spectral in-
tensity and thus changes in protein content
are balanced; samples with high normalisa-
tion factor are excluded from the analysis.
Finally, in postanalytical stage, adequate sta-
tistics, according to aim of  the experiment,
should be applied and proper methods for
identification of  peaks or gel spots selected
– this is important for confirmation of  the
identity of  detected proteins (Scheme 2). Due
to space limits we provide here only some
references on statistical analyses in pro-
teomics14-17 and before concluding we wish
to emphasize once more general aspects of
standardization process.
General Quality Assurance
Though it is time consuming and sometimes
tricky, one should aim at achieving and run-
ning proper Quality Control (QC). This in-
cludes adopting sampling and storage pro-
tocols and performance of  regular checks
including personnel (operator) to eliminate
subjective factors and clerical errors, per-
forming pipette calibration, checking for
uniformity and quality of  used reagents and
materials (chips, gels, etc.) and importantly
testing for reproducibility18, e.g. employing
QC samples to check for intra/inter assay
variability. Usage of  certified standards,
which enable calibration in the required range
and which are properly reconstituted, aliq-
uoted and stored, is mandatory. Adhering to
this complex QC measures, random and sys-
tematic errors should be eliminated to min-
imum. Finally, recording of  all crucial pro-
cedures especially during preanalytical and
analytical stages is critical because it allows
repetition of  experiments and namely anal-
ysis of  all sequential steps if  a problem arose.
Of  particular importance is recording of
storage & handling conditions, instrument
calibration and reproducibility records.
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Scheme 2. Protein identification strategies X axis:
amount of information, Y-axis: confidence level, MS: mass
spectrometry
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Conclusion
We are aware that this brief  overview, with
only few details limited to SELDI-TOF MS,
can provide only an introductory insight into
the problem what to do in order to obtain
valid data from a proteomic experiment. In
an ideal case, a reader may “take home” our
message that “Even the best idea does not
quarantee valid outcome if  critical methodi-
cal points are neglected” and vice versa that
“No quality control can assure that good
research or clinical data are achieved if  the
idea & experimental design is flawed”.
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